-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Financial App News, Hanson Pharmaceuticals (03692.HK) announced that the monotherapy for ametinib (overseas product name: Aumseqa®) was approved for listing in the European Union (EU) after the European Medicines Agency (EMA) Human Medicines Committee (CHMP) issued an implementation decision on September 25, 2026. The European Commission (EC) General Directorate of Health and Food Safety issued an implementation decision on September 25, 2026.

Zhitongcaijing·09/27/2026 10:33:01
Listen to the news
According to Zhitong Financial App News, Hanson Pharmaceuticals (03692.HK) announced that the monotherapy for ametinib (overseas product name: Aumseqa®) was approved for listing in the European Union (EU) after the European Medicines Agency (EMA) Human Medicines Committee (CHMP) issued an implementation decision on September 25, 2026. The European Commission (EC) General Directorate of Health and Food Safety issued an implementation decision on September 25, 2026.